May 2009 Volume 6 Number 5
Visit Nature Reviews Urology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=26&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Urology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=17&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=29&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
*********************************************************************
Nature Reviews Urology Impact Factor: 2.104*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Nature Reviews Urology brings all the qualities of the top-ranked life
sciences series to the clinical sciences and is a valuable resource for
practicing physicians and clinical academics.
Visit Nature Reviews Urology online at
http://links.ealert.nature.com/ctt?kn=86&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
and keep up-to-date with the latest advances in urology.
=====================================================================
----------------------
EDITORIAL
----------------------
Safety in surgery: the checklist
Peter T. Scardino
p235 | doi:10.1038/nrurol.2009.76
http://links.ealert.nature.com/ctt?kn=67&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Prostate Cancer: Does PSA screening do more harm than good?
p237 | doi:10.1038/nrurol.2009.63
http://links.ealert.nature.com/ctt?kn=88&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Urinary Incontinence: Gel calms overactive bladders
p238 | doi:10.1038/nrurol.2009.61
http://links.ealert.nature.com/ctt?kn=18&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Biomarkers: Circulating tumor cells in prostate cancer
p238 | doi:10.1038/nrurol.2009.62
http://links.ealert.nature.com/ctt?kn=4&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Male circumcision: HSV-2 and HPV
p239 | doi:10.1038/nrurol.2009.59
http://links.ealert.nature.com/ctt?kn=56&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Prostate Cancer: Amelioration of risk by omega-3 modified by COX-2
p240 | doi:10.1038/nrurol.2009.66
http://links.ealert.nature.com/ctt?kn=73&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
IN BRIEF
Radiotherapy | Pain | Prostate Cancer | Pediatrics
p240 | doi:10.1038/nrurol.2009.73
http://links.ealert.nature.com/ctt?kn=45&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Bladder Cancer: Intravesical MCC for bladder cancer
p241 | doi:10.1038/nrurol.2009.64
http://links.ealert.nature.com/ctt?kn=38&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Sexual Dysfunction: Erectile problems in teenagers commonly miscategorized
as psychogenic
p241 | doi:10.1038/nrurol.2009.65
http://links.ealert.nature.com/ctt?kn=85&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Infertility and cancer
p242 | doi:10.1038/nrurol.2009.31
http://links.ealert.nature.com/ctt?kn=76&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Pediatrics: Treating OAB in children
p242 | doi:10.1038/nrurol.2009.43
http://links.ealert.nature.com/ctt?kn=78&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Bladder Cancer: Aspirin reduces bladder cancer recurrence
p243 | doi:10.1038/nrurol.2009.58
http://links.ealert.nature.com/ctt?kn=32&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
IN BRIEF
Male factor infertility | Surgery | Sexual dysfunction | Clinical trials
p243 | doi:10.1038/nrurol.2009.72
http://links.ealert.nature.com/ctt?kn=58&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Quality of life: Cancer survivors more likely to face unemployment
p244 | doi:10.1038/nrurol.2009.37
http://links.ealert.nature.com/ctt?kn=44&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Prostate Cancer: Sarcosine indicates metastatic potential
p244 | doi:10.1038/nrurol.2009.60
http://links.ealert.nature.com/ctt?kn=37&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Surgery: Can checklists improve surgical outcomes?
John D. Birkmeyer and David C. Miller
p245 | doi:10.1038/nrurol.2009.57
In the quest to reduce the incidences of morbidity and mortality associated
with surgery, a number of initiatives are being explored. Could a simple
checklist provide an effective means of improving surgical outcome?
http://links.ealert.nature.com/ctt?kn=60&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Urinary incontinence: Can weight loss treat urinary incontinence in obese
women?
Christina Aye, Natalia Price and Simon R. Jackson
p247 | doi:10.1038/nrurol.2009.74
New research confirms that weight loss is an effective first-line
intervention for overweight or obese women with urinary incontinence.
Such patients should be encouraged to lose weight, but must also be given
access to a full range of treatment options.
http://links.ealert.nature.com/ctt?kn=80&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Prostate cancer: Thalidomide for prostate cancer: is there progress?
Eleni Efstathiou and Christopher J. Logothetis
p248 | doi:10.1038/nrurol.2009.68
Upon its 'reinvention', thalidomide was quickly applied to
'microenvironment-dependent' diseases such as multiple myeloma, yet its
role in the solid tumor spectrum has not been validated. A report into
recurrent prostate cancer by Figg et al. shows that thalidomide can reduce
time to PSA progression in patients treated with androgen deprivation therapy.
http://links.ealert.nature.com/ctt?kn=25&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Prostate cancer: Local control and radiotherapy matter in prostate cancer
Seth A. Rosenthal
p250 | doi:10.1038/nrurol.2009.56
In a study published in The Lancet, long-term androgen suppression (AS)
combined with radiotherapy, compared with AS alone, improved outcomes in
patients with locally advanced but nonmetastatic prostate cancer. The
combined therapy significantly reduced prostate-cancer-specific deaths at
10 years from 23.9% to 11.9% (P <0.001), and improved overall survival.
http://links.ealert.nature.com/ctt?kn=61&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Prostate cancer: Cardiovascular mortality and androgen deprivation
Shehzad Basaria
p252 | doi:10.1038/nrurol.2009.75
Every treatment has unintended adverse effects, and androgen deprivation
therapy (ADT) for prostate cancer is no exception. A flurry of reports
has implicated ADT in increasing cardiovascular risk and mortality. In
this regard, the 2009 study by Efstathiou and colleagues is a notable
exception.
http://links.ealert.nature.com/ctt?kn=97&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
----------------------
REVIEWS
----------------------
The use of PCA3 in the diagnosis of prostate cancer
Daphne Hessels and Jack A. Schalken
p255 | doi:10.1038/nrurol.2009.40
The discovery that prostate cancer gene 3 (PCA3) is overexpressed in
malignant prostate cells has led to the development of a PCA3 urine test
for prostate cancer. In this Review, the authors discuss the molecular
marker PCA3 and its application in the diagnosis of prostate cancer and
use as a prognostic indicator in men with prostate cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=23&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=22&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Evaluation and management of priapism: 2009 update
Yun-Ching Huang, Ahmed M. Harraz, Alan W. Shindel and Tom F. Lue
p262 | doi:10.1038/nrurol.2009.50
Drawing on their own considerable experience, Huang and colleagues, from
the University of California, San Francisco, review current therapies and
emerging treatments for the management of priapism. Medical and surgical
approaches to both the ischemic and nonischemic subtypes of this disorder
are discussed.
Abstract: http://links.ealert.nature.com/ctt?kn=92&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=90&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Current management of emphysematous pyelonephritis
Alan R. Pontin and Richard D. Barnes
p272 | doi:10.1038/nrurol.2009.51
Emphysematous pyelonephritis is a severe, necrotizing, renal parenchymal
infection that is characterized by the production of intraparenchymal gas.
Predominantly affecting female diabetics, the presentation of this disorder
has changed over the past 25 years. A more conservative approach to treatment
is now recommended.
Abstract: http://links.ealert.nature.com/ctt?kn=79&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=11&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Glutathione S-transferases in kidney and urinary bladder tumors
Tatjana Simic et al.
p281 | doi:10.1038/nrurol.2009.49
Glutathione S-transferases protect cells from toxic electrophilic compounds,
including potential carcinogens, by catalyzing their conjugation to
glutathione. These enzymes are found in both kidney and urothelial tissue.
In this Review, Simic and colleagues discuss the relationships between
enzyme polymorphism, altered expression, susceptibility to kidney and bladder
tumors, and resistance to chemotherapy.
Abstract: http://links.ealert.nature.com/ctt?kn=9&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=93&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Visit the Nature Reviews Urology website:
- Advanced online publication
- Search across related content from nature.com
- Web feeds (RSS)
- Downloadable PowerPoint slides of figures and supplementary information
http://links.ealert.nature.com/ctt?kn=86&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=14&m=32897657&r=MTc2NDg0NjM5NAS2&b=2&j=NDg1NjUwOTES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration
department:
registration@nature.com
For print subscription enquiries, please contact our subscription
department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
